ArticleKidney3602026
Neurofilament Light Chain and Cognitive Dysfunction in Patients Undergoing Hemodialysis: A Cross-Sectional Exploratory Study.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
key pointsBlood biomarkers related to amyloid β and neurofilament light chain are used to predict cognitive decline in the general population. Evidence for their usefulness is lacking in patients receiving hemodialysis despite their high risk of cognitive impairment. Neurofilament light chain levels were negatively associated with cognitive function, whereas the amyloid β ratio was not.
backgroundCognitive dysfunction is frequently observed in patients undergoing hemodialysis in clinical settings; however, its pathophysiology remains uncertain. In recent years, noninvasive blood biomarkers have garnered increasing attention in predicting Alzheimer's disease development. Within the general population, neurofilament light chain (NfL) levels have been used to prognosticate changes in cognitive function alongside the amyloid β (A β ) 1-42/1-40 ratio. Nevertheless, this has not been studied in patients with CKD, particularly those undergoing hemodialysis.
methodsThis exploratory cross-sectional study investigated the association of the serum A β 1-42/1-40 ratio and NfL levels with cognitive function assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), in patients undergoing hemodialysis.
resultsWe included 384 patients with a median age of 74 (interquartile range [IQR], 70-80) years. The median (IQR) MoCA and MMSE scores were 25 (22-26) and 28 (26-29), respectively. The median (IQR) A β 1-42/1-40 ratio and NfL level were 0.04 (0.03-0.06) and 196.2 pg/ml (146.5-262.2), respectively. The multivariate linear regression analysis indicated a weak negative association between the log-transformed NfL levels and cognitive function, after adjusting for confounding factors including age ( β coefficient [95% confidence interval], -0.98 [-1.81 to -0.15]; P = 0.021 for MoCA and -0.66 [-1.32 to -0.01]; P = 0.046 for MMSE). However, the A β 1-42/1-40 ratio was not associated with cognitive function.
conclusionsOur exploratory analysis identified a weak negative association between serum NfL levels and cognitive function in patients undergoing hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.